0001104659-23-094746.txt : 20230824 0001104659-23-094746.hdr.sgml : 20230824 20230824080510 ACCESSION NUMBER: 0001104659-23-094746 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230824 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230824 DATE AS OF CHANGE: 20230824 FILER: COMPANY DATA: COMPANY CONFORMED NAME: COLLEGIUM PHARMACEUTICAL, INC CENTRAL INDEX KEY: 0001267565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37372 FILM NUMBER: 231198936 BUSINESS ADDRESS: STREET 1: 100 TECHNOLOGY CENTER DRIVE CITY: STOUGHTON STATE: MA ZIP: 02072 BUSINESS PHONE: 781-713-3699 MAIL ADDRESS: STREET 1: 100 TECHNOLOGY CENTER DRIVE CITY: STOUGHTON STATE: MA ZIP: 02072 FORMER COMPANY: FORMER CONFORMED NAME: COLLEGIUM PHARMACEUTICAL INC DATE OF NAME CHANGE: 20031020 8-K 1 tm2323003d2_8k.htm FORM 8-K
0001267565 false 0001267565 2023-08-24 2023-08-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 24, 2023

 

COLLEGIUM PHARMACEUTICAL, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Virginia   001-37372   03-0416362
(State or Other Jurisdiction
of Incorporation or Organization)		   (Commission File Number)   (IRS Employer Identification
No.)

 

100 Technology Center Drive
Suite 300
Stoughton, MA 02072
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (781) 713-3699

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, par value $0.001 per share COLL The NASDAQ Global Select Market

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

Item 8.01  Other Information.

 

On August 24, 2023, Collegium Pharmaceutical, Inc. issued a press release announcing that the U.S. Food and Drug Administration has granted New Patient Population exclusivity for Nucynta®, an immediate release formulation of tapentadol. This grant extends the period of U.S. exclusivity for Nucynta from June 27, 2025 to July 3, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

 

Item 9.01 Financial Statements and Exhibits.

 

99.1 Press Release, dated August 24, 2023
   
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: August 24, 2023 Collegium Pharmaceutical, Inc.
     
  By: /s/ Colleen Tupper
    Name: Colleen Tupper
    Title: Executive Vice President and Chief Financial Officer

 

 

 

 EX-99.1 2 tm2323003d2_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

 

Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026

 

STOUGHTON, Mass., Aug. 24, 2023 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted New Patient Population exclusivity for Nucynta®, an immediate release formulation of tapentadol. This grant extends the period of U.S. exclusivity for Nucynta from June 27, 2025 to July 3, 2026.

 

The exclusivity determination is based on data from pediatric trials which were submitted in response to the FDA's Pediatric Written Request to evaluate the use of Nucynta as a treatment for pain in pediatric patients aged 6 years and older.

 

Nucynta is currently approved in the U.S. for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults and pediatric patients aged 6 years and older with a body weight of at least 40kg.

 

“We believe that this grant of additional exclusivity recognizes the importance of Nucynta in the treatment of acute, severe pain,” said Thomas Smith, M.D., Collegium’s Chief Medical Officer. “We remain committed to the Nucynta Franchise, including through continued pursuit of a pediatric extension which would extend exclusivity of the entire Nucynta Franchise an additional six months, to December 2025 for Nucynta ER and January 2027 for Nucynta.”

 

About Collegium Pharmaceutical, Inc.

 

Collegium is a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.

 

NUCYNTA® (tapentadol) INDICATIONS AND USAGE

 

NUCYNTA® (tapentadol) tablets are:

·A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage short term (acute) pain in adults and children 6 years of age and older who weigh at least 88 pounds (40 kg), when other pain treatments such as non-opioid pain medicines do not treat your pain well enough or you cannot tolerate them.
·An opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed, you are at risk for opioid addiction, abuse, and misuse that can lead to death.

 

 

 

 

 

 

IMPORTANT SAFETY INFORMATION ABOUT NUCYNTA TABLETS

 

 

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF NUCYNTA TABLETS

 

Addiction, Abuse, and Misuse

Because the use of NUCYNTA tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess regularly for the development of these behaviors and conditions.

 

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of NUCYNTA tablets, especially during initiation of NUCYNTA tablets or following a dose increase. To reduce the risk of respiratory depression, proper dosing and titration of NUCYNTA tablets are essential.

 

Accidental Ingestion

Accidental ingestion of even one dose of NUCYNTA tablets, especially by children, can result in a fatal overdose of tapentadol.

 

Risks From Concomitant Use With Benzodiazepines or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of NUCYNTA tablets and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.

 

Neonatal Opioid Withdrawal Syndrome

If opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of Neonatal Opioid Withdrawal Syndrome which may be life threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery.

 

Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)

Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription.

 

 

Important information about NUCYNTA tablets:

·Get emergency help or call 911 right away if you take too much NUCYNTA (overdose) tablets. When you first start taking NUCYNTA tablets, when your dose is changed, or if you take too much (overdose), serious or life-threatening breathing problems that can lead to death may occur. Talk to your healthcare provider about naloxone, a medicine for the emergency treatment of an opioid overdose.
·Taking NUCYNTA tablets with other opioid medicines, benzodiazepines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems, coma, and death.
·Never give anyone else your NUCYNTA tablets. They could die from taking it. Selling or giving away NUCYNTA tablets is against the law.
·Store NUCYNTA tablets securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home.

 

Do not take NUCYNTA tablets if you have:

·severe asthma, trouble breathing, or other lung problems.
·a bowel blockage or have narrowing of the stomach or intestines.

 

 

 

 

 

 

Before taking NUCYNTA tablets, tell your healthcare provider if you have a history of:

·head injury, seizures
·problems urinating
·abuse of street or prescription drugs, alcohol addiction, opioid overdose or mental health problems
·liver, kidney, thyroid problems
·pancreas or gallbladder problems

 

Tell your healthcare provider if you:

·notice your pain getting worse. If your pain gets worse after you take NUCYNTA tablets, do not take more NUCYNTA tablets without first talking to your healthcare provider. Tell your healthcare provider if the pain that you have increases, if you feel more sensitive to pain, or if you have new pain after taking NUCYNTA tablets.
·are pregnant or planning to become pregnant. Use of NUCYNTA tablets for an extended period of time during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not recognized and treated.
·are breastfeeding. NUCYNTA tablets pass into breast milk and may harm your baby.
·are living in a household where there are small children or someone who has abused street or prescription drugs.
·are taking prescription or over-the-counter medicines, vitamins, or herbal supplements. Taking NUCYNTA tablets with certain other medicines can cause serious side effects that could lead to death.

 

When taking NUCYNTA tablets:

·Do not change your dose. Take NUCYNTA tablets exactly as prescribed by your healthcare provider. Use the lowest dose possible for the shortest time needed.
·For acute (short-term) pain, you may only need to take NUCYNTA tablets for a few days. You may have some NUCYNTA tablets left over that you did not use. See disposal information at the bottom of this section for directions on how to safely throw away (dispose of) your unused NUCYNTA tablets.
·Take your prescribed dose every 4-6 hours, at the same time every day. Do not take more than your prescribed dose. If you miss a dose, take your next dose at your usual time.
·Call your healthcare provider if the dose you are taking does not control your pain.
·If you have been taking NUCYNTA tablets regularly, do not stop taking NUCYNTA tablets without talking to your healthcare provider.
·Dispose of expired, unwanted, or unused NUCYNTA Tablets by promptly flushing down the toilet, if a drug take-back option is not readily available. Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.

 

While taking NUCYNTA tablets, DO NOT:

·Drive or operate heavy machinery, until you know how NUCYNTA tablets affect you. NUCYNTA tablets can make you sleepy, dizzy, or lightheaded.
·Drink alcohol or use prescription or over-the-counter medicines that contain alcohol. Using products containing alcohol during treatment with NUCYNTA tablets may cause you to overdose and die.

 

The possible side effects of NUCYNTA tablets:

·constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness, abdominal pain. Call your healthcare provider if you have any of these symptoms and they are severe.

 

 

 

 

 

 

Get emergency medical help or call 911 right away if you have:

·trouble breathing, shortness of breath, fast heartbeat, chest pain, swelling of your face, tongue, or throat, extreme drowsiness, light-headedness when changing positions, feeling faint, agitation, high body temperature, trouble walking, stiff muscles, or mental changes such as confusion.

 

These are not all of the possible side effects of NUCYNTA tablets. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. For more information, go to dailymed.nlm.nih.gov.

 

See full Prescribing Information, including Boxed Warning on Addiction, Abuse and Misuse and other serious risks, and the Medication Guide accompanying this piece or at Nucynta.com/IRpi. Speak to your healthcare provider if you have questions about Nucynta.

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “forecasts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements related to our pursuit of a pediatric extension of exclusivity for the Nucynta franchise. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results, performance, or achievements to differ materially from the company's current expectations, including the risks described under the heading "Risk Factors" in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other filings with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

 

Investor Contact:

Christopher James, M.D.

Vice President, Investor Relations

ir@collegiumpharma.com

 

Media Contact:

Marissa Samuels

Vice President, Corporate Communications

communications@collegiumpharma.com

 

 

 EX-101.SCH 3 coll-20230824.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 coll-20230824_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 coll-20230824_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2323003d2_ex99-1img01.jpg GRAPHIC begin 644 tm2323003d2_ex99-1img01.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 24, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 24, 2023
Entity File Number 001-37372
Entity Registrant Name COLLEGIUM PHARMACEUTICAL, INC.
Entity Central Index Key 0001267565
Entity Tax Identification Number 03-0416362
Entity Incorporation, State or Country Code VA
Entity Address, Address Line One 100 Technology Center Drive
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Stoughton
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02072
City Area Code 781
Local Phone Number 713-3699
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol COLL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2323003d2_8k_htm.xml IDEA: XBRL DOCUMENT 0001267565 2023-08-24 2023-08-24 iso4217:USD shares iso4217:USD shares 0001267565 false 8-K 2023-08-24 COLLEGIUM PHARMACEUTICAL, INC. VA 001-37372 03-0416362 100 Technology Center Drive Suite 300 Stoughton MA 02072 781 713-3699 Common stock, par value $0.001 per share COLL NASDAQ false false false false false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ "(" / M " 740 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " "D0!A7)!Z; MHJT #X 0 &@ @ '5$0 >&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;'-02P$"% ,4 " "D0!A799!YDAD! #/ P $P M @ &Z$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" $ %% ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://collegiumpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2323003d2_8k.htm coll-20230824.xsd coll-20230824_lab.xml coll-20230824_pre.xml tm2323003d2_ex99-1.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2323003d2_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2323003d2_8k.htm" ] }, "labelLink": { "local": [ "coll-20230824_lab.xml" ] }, "presentationLink": { "local": [ "coll-20230824_pre.xml" ] }, "schema": { "local": [ "coll-20230824.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "coll", "nsuri": "http://collegiumpharma.com/20230824", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2323003d2_8k.htm", "contextRef": "AsOf2023-08-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://collegiumpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2323003d2_8k.htm", "contextRef": "AsOf2023-08-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001104659-23-094746-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-094746-xbrl.zip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end